- Home
- KLG vs SPRY Comparison
KLG vs SPRY Comparison
Compare KLG & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLG
- SPRY
- Stock Information
- Founded
- KLG 2022
- SPRY 2015
- Country
- KLG United States
- SPRY United States
- Employees
- KLG N/A
- SPRY N/A
- Industry
- KLG Packaged Foods
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- KLG Consumer Staples
- SPRY Health Care
- Exchange
- KLG Nasdaq
- SPRY Nasdaq
- Market Cap
- KLG 2.0B
- SPRY 1.8B
- IPO Year
- KLG N/A
- SPRY N/A
- Fundamental
- Price
- KLG $22.98
- SPRY $9.86
- Analyst Decision
- KLG Hold
- SPRY Strong Buy
- Analyst Count
- KLG 7
- SPRY 5
- Target Price
- KLG $20.57
- SPRY $31.00
- AVG Volume (30 Days)
- KLG 1.1M
- SPRY 3.1M
- Earning Date
- KLG 11-06-2025
- SPRY 11-12-2025
- Dividend Yield
- KLG 2.87%
- SPRY N/A
- EPS Growth
- KLG N/A
- SPRY N/A
- EPS
- KLG 0.35
- SPRY N/A
- Revenue
- KLG $2,605,000,000.00
- SPRY $112,339,000.00
- Revenue This Year
- KLG N/A
- SPRY N/A
- Revenue Next Year
- KLG N/A
- SPRY $188.92
- P/E Ratio
- KLG $66.48
- SPRY N/A
- Revenue Growth
- KLG N/A
- SPRY 22367.80
- 52 Week Low
- KLG $14.80
- SPRY $9.38
- 52 Week High
- KLG $23.56
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- KLG 62.51
- SPRY 28.85
- Support Level
- KLG $22.96
- SPRY $9.38
- Resistance Level
- KLG $23.01
- SPRY $10.15
- Average True Range (ATR)
- KLG 0.05
- SPRY 0.63
- MACD
- KLG -0.05
- SPRY 0.02
- Stochastic Oscillator
- KLG 71.87
- SPRY 13.86
About KLG WK Kellogg Co
WK Kellogg is the second-largest cereal manufacturer in North America. Its cereal brands include Special K, Frosted Flakes, Raisin Bran, Froot Loops, Frosted Mini-Wheats, Kashi, Corn Flakes, Rice Krispies, Apple Jacks, and Bear Naked. The company was spun off from the former Kellogg business, now known as Kellanova, where the former firm's global snacks portfolio and international cereal brands now reside. WK Kellogg, which began trading independently in October 2023, generates the bulk of its sales (about 88% of its fiscal 2024 base) in the US.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.